Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals Inc operates in various business sectors.
Amphastar Pharmaceuticals Inc (29A) - Net Assets
Latest net assets as of June 2024: €713.35 Million EUR
Based on the latest financial reports, Amphastar Pharmaceuticals Inc (29A) has net assets worth €713.35 Million EUR as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.49 Billion) and total liabilities (€778.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €713.35 Million |
| % of Total Assets | 47.83% |
| Annual Growth Rate | 11.91% |
| 5-Year Change | 49.56% |
| 10-Year Change | N/A |
| Growth Volatility | 8.53 |
Amphastar Pharmaceuticals Inc - Net Assets Trend (2018–2023)
This chart illustrates how Amphastar Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Amphastar Pharmaceuticals Inc (2018–2023)
The table below shows the annual net assets of Amphastar Pharmaceuticals Inc from 2018 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €639.42 Million | +20.95% |
| 2022-12-31 | €528.66 Million | +18.66% |
| 2021-12-31 | €445.52 Million | -0.71% |
| 2020-12-31 | €448.72 Million | +4.96% |
| 2019-12-31 | €427.53 Million | +17.34% |
| 2018-12-31 | €364.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Amphastar Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 506.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €409.27 Million | 64.01% |
| Other Components | €230.15 Million | 35.99% |
| Total Equity | €639.42 Million | 100.00% |
Amphastar Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Amphastar Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BioAdaptives Inc
PINK:BDPT
|
$147.23K |
|
Focus Home Interactive Société anonyme
STU:0HF
|
$147.49K |
|
Sparindex INDEX Europa Forsvar
CO:SPIIEF
|
$147.51K |
|
NHK SPRING (NHK.SG)
STU:NHK
|
$147.52K |
|
ROLLS-ROYCE HLDGS
MU:RRU
|
$147.17K |
|
Wealth Invest AKL AlphaCura 0/50/100 W
CO:WEIACW
|
$147.07K |
|
R STAHL N
BE:RSL2
|
$147.02K |
|
MEDION
MU:MDN
|
$147.01K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Amphastar Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 528,658,000 to 639,421,000, a change of 110,763,000 (21.0%).
- Net income of 137,545,000 contributed positively to equity growth.
- Share repurchases of 58,144,000 reduced equity.
- Other factors increased equity by 31,362,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €137.54 Million | +21.51% |
| Share Repurchases | €58.14 Million | -9.09% |
| Other Changes | €31.36 Million | +4.9% |
| Total Change | €- | 20.95% |
Book Value vs Market Value Analysis
This analysis compares Amphastar Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.17x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.19x to 1.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | €7.13 | €15.63 | x |
| 2019-12-31 | €8.19 | €15.63 | x |
| 2020-12-31 | €8.47 | €15.63 | x |
| 2021-12-31 | €9.34 | €15.63 | x |
| 2022-12-31 | €10.99 | €15.63 | x |
| 2023-12-31 | €13.30 | €15.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Amphastar Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 21.51%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 21.34%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 2.37x
- Recent ROE (21.51%) is above the historical average (8.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -1.73% | -1.95% | 0.57x | 1.54x | €-38.98 Million |
| 2019 | 1.06% | 1.21% | 0.57x | 1.54x | €-34.10 Million |
| 2020 | 0.35% | 0.40% | 0.55x | 1.57x | €-38.83 Million |
| 2021 | 13.94% | 14.19% | 0.65x | 1.51x | €17.56 Million |
| 2022 | 17.29% | 18.31% | 0.67x | 1.40x | €38.52 Million |
| 2023 | 21.51% | 21.34% | 0.43x | 2.37x | €73.60 Million |
Industry Comparison
This section compares Amphastar Pharmaceuticals Inc's net assets metrics with peer companies in the same industry.
No peer company data available for comparison.